Biomm S.A. (BOVESPA: BIOM3)
Health Care · Biotechnology · BR
R$6.60
+15.79% today · +2.5% 1Y
Biomm S.A. (BOVESPA: BIOM3) operates in the Biotechnology industry within the Health Care sector. The company is valued at $175.04M and employs 130 people.
Over the last twelve months the share price has gained 2.5%, trading between 4.82 and 10.39.
Tweenvest scores Biomm S.A. across four factors: quality 38/100, value 43/100, growth 100/100. Its strongest factor is growth.
BIOM3 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $175.04M
- Revenue (TTM)
- $74.20M
- P/E
- 30.00
- EPS
- 0.22
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- R$10.39
- 52-week low
- R$4.82
- Avg volume (3M)
- —
- Shares outstanding
- 136.85M
- Employees
- 130
- Next earnings
- —
About Biomm S.A.
Biomm S.A. is a biotechnology enterprise based in Brazil. Its diverse product portfolio features pharmaceutical and healthcare solutions, including AFREZZA, a human insulin administered as an inhalation powder, and GLARGILIN, a type of glargine insulin. The company also supplies HERZUMA, a trastuzumab, and CONFORT CARE, a moisturizing foot cream. Biomm S.A. was established in 2001 and maintains its headquarters in São Paulo, Brazil.
- ISIN
- BRBIOMACNOR2
- Founded
- 2001
- Listed since
- Jan 11, 2000
- Exchange
- Bolsa de Valores de Sao Paulo
- Currency
- BRL
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.